Ciba-Geigy Corporation

Novartis Ag

Isis Pharmaceuticals, Inc.

Novartis Corporation

Other

Intermune, Inc.

Sanofi Pasteur Sa

Ciba-Geigy Ag

Biomarin Pharmaceutical Inc.

Ratiopharm Gmbh

Solvias Ag

Merck Eprova Ag

Sanofi Pasteur Inc.

Pierre Martin

Daniel Bellus

Eginhard Steiner

Hans Greuter

Karl-Heinz Altmann

Brett P Monia

Laurenz Gsell

Robert W Lang

Andreas Schumacher

Dirk Spielvogel

Andreas Boudier

Steven Wade Andrews

Yutong Jiang

Nicholas M Dean

Peter Ackermann

Timothy S Kercher

Bin Wang

Scott D Seiwert

Lawrence M Blatt

Paul Nichols

Weidong Liu

John G Dingwall

Michael Lyon

April L Kennedy

Oreste Ghisalba

C Todd Eary

Dietmar Flubacher

Robert J Kaus

Tarek Sammakia

Bradley Barnett

Markus Mueller

Phillip Dan Cook

Jozef Drabek

Willy Meyer

Josef Ehrenfreund

Manfred Boger

Rudolf Moser

Felix Spindler

Viola Groehn

Ulrich Berens

Bernard Cuenoud

Heinz Ernst Moser

Peter Baumeister

Marc Thommen

Benoît Pugin

Oliver Dosenbach

Martin Kesselgruber

Hansjurg Wetter

Paul Radimerski

Frédéric Maurice Naud

Guy Joel Marais

Markus Müller

Guy Joel Christian Marais

Francois J Natt

Gianpietro Melone

Francois Jean Charles Natt

The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: in which: in which R'b is as defined above for (I), in which R&#x2033; is as defined in claim, and also the compounds of formula (III).

Process for preparing prophyrin derivatives, such as protoprophyrin (IX) and synthesis intermediates

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: in which: in which R'b is as defined above for (I),and a dipyrromethane of formula (III): in which R&#x2033; is as defined in claim, and also the compounds of formula (III).

Process for preparing porphyrin derivatives, such as protoporphyrin (IX) and synthesis intermediates

The present invention provides a process for the sulfurization of phosphorus-containing compounds. More particularly, the process involves contacting the compound to be sulfurized with a sulfur transfer reagent as defined hereinbefore in a solvent or a mixture of solvents.

Organic compounds

The invention relates to a process for the manufacture of an 1,2,4-triazol-1-yl compound of the formula [A], or a salt thereof, wherein each of R3 and R4 is hydrogen or lower alkyl, said process comprising reacting a hydrazine compound of the formula [B] wherein R is hydrogen or acyl, R2 is hydrogen or a protecting group, are hydrogen or lower alkyl, and R6 is hydrogen or COOR7, or a salt thereof, with a 1,2,4-triazolyl forming reagent. In addition, novel intermediates for the synthesis of the anti-migraine agent Rizatriptan and methods for their synthesis are presented.

Synthesis methods and intermediates for the manufacture of Rizatriptan

Process for the preparation of tetrahydrobiopterin from neopterin and/or 6-substituted pterins with an improved yield and a high stereoselectivity. Also disclosed herein are novel individual intermediates prepared in the preparation of tetrahydrobiopterin, such as selectively protected neopterin useful for the preparation of tetrahydrobiopterin.

Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin

1,1'-Biphenyl-2,2&#x2032;-diphosphines having at least one amine substituent in the para position relative to the phosphine group and having the formulae are ligands for metal complexes which serve as catalysts for asymmetric addition reactions of prochiral organic compounds and whose catalytic properties can be tailored specifically to particular substrates by substitution of the amine group.

Amine-substituted biphenyldiphosphines

The invention relates to a process for the sulfurization of phosphorus-containing compounds which comprises contacting the phosphorus compound to be sulfurized with a sulfur transfer reagent of formula (I) wherein

Process for the sulfurization of a phosphorus-containing compound

2&prime;-substituted nucleosides and oligonucleotide derivatives

Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2&prime;-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to ooligonucleotide therapeutics.

Sugar-modified gapped oligonucleotides

Phosphorus containing cyclic nucleotides

Methoxyethoxy oligonucleotides for modulation of protein kinase C

The invention relates to a compound of formula (I) ##STR1## Wherein: B is adenine, guanine or hypoxanthine Z is hydrogen or a negative charge R is --[CH.sub.2 CH(R.sup.1)--O].sub.n -R.sup.2, --CH.sub.2 CH.sub.2 X, in which R.sup.1 is hydrogen or (C.sub.1 -.sub.6) alkyl R.sup.2 is hydrogen or (C.sub.1 -.sub.6) alkyl n is a number from 1 to 6 X is OH, F, NR.sup.3 R.sup.4 R.sup.3 and R.sup.4 are independently from each other hydrogen or (C.sub.1 -.sub.6) alkyl and to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.

Method for treating cyclic phosphate compound

Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently of the other hydrogen or a protecting group, or

Oligonucleotides having 2'-ether groups

Growing community of inventors

Rheinfelden, Switzerland

Pierre Martin